Soluble guanylate cyclase activators

US8455638B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Amy R. Bittner · Scotch Plains, US
• Ronald Kim · Essen, DE
• John W. Mirc · Tokyo, JP
• Emma R. Parmee · Scotch Plains, US
• Christopher Joseph Sinz · Middletown, US
• Qiang Tan · Westfield, US

Key dates

• Filing date: Sep 2, 2008
• Grant date: Jun 4, 2013
• Expiry date: Feb 14, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.